Key Insights• According to the research report, "South Korea Cardiovascular Devices Market Outlook, 2031," published by Actual Market Research, the South Korea Cardiovascular Devices Market is expected to reach a market size of more than 1.26 Billion by 2031.• The rapid shift toward minimally invasive structural heart interventions especially Transcatheter Aortic Valve Implantation (TAVI) and Transcatheter Mitral Valve Repair (TMVR) is significantly accelerating procedural volume across South Korea's tertiary care centers. Following National Health Insurance (NHI) scheme policy updates that broadened reimbursement coverage for TAVI to include intermediate-risk patients, annual TAVI procedure counts jumped over 35% in public and private medical hubs. A notable technological breakthrough includes the domestic commercialization and pre-market clearance of indigenous bioresorbable cardiac scaffolds, next-generation 3D-printed structural heart mapping models, and leadless dual-chamber pacemakers cleared by the Ministry of Food and Drug Safety (MFDS).• Following updated regulatory and reimbursement frameworks for Software as a Medical Device (SaMD) and post-discharge digital telemetry, South Korean cardiologists regularly deploy long-wear continuous patch ECGs, smart implantable loop recorders (ILRs), and cloud-connected cardiac rhythm devices. By embedding machine learning algorithms directly into remote monitoring platforms, these systems automatically screen continuous telemetry for transient atrial fibrillation and early hemodynamic markers of heart failure, reducing heart failure readmission rates by more than 40% in multi-center clinical evaluations.• Strict regulatory oversight enforced by the MFDS, combined with stringent bench-testing and thrombogenicity standards for Class III/IV medical devices, creates ongoing market access friction. Elevated compliance documentation requirements such as mandatory 600-million-cycle durability testing for prosthetic heart valves have extended regulatory approval timelines for high-risk implants. Concurrently, centralized Health Insurance Review and Assessment Service (HIRA) price negotiations enforce strict cost-containment across mature device lines like standard drug-eluting stents (DES) and diagnostic catheters, prompting medical device vendors to focus commercial strategies on non-commoditized, high-tier interventional platforms.Market Outlook• Supported by federal initiatives aimed at relieving bed capacity pressures in Seoul's major university medical centers, regional healthcare networks are expanding capital investments in compact, highly mobile diagnostic hardware, single-use electrophysiology devices, and remote patient monitoring software.

Medical device vendors that deliver integrated, cloud-compatible diagnostic platforms and low-profile interventional hardware facilitating same-day discharge will secure preferential procurement standing across public tenders and private hospital systems.• Critical industry trade associations and regulatory/clinical bodies like the Korean Medical Devices Industry Association (KMDIA), the Korean Society of Cardiology (KSC), the Korean Society of Interventional Cardiology (KSIC), HIRA, and the MFDS continue to shape clinical practice guidelines, reimbursement tiers, and device safety standards, while leading domestic and multinational companies such as Medtronic, Abbott Laboratories, Boston Scientific, Edwards Lifesciences, Osstem Cardio, BIOTRONIK, Siemens Healthineers, GE Healthcare, and Terumo Corporation drive ongoing commercial deployment across South Korea.Market DynamicsDriver: Demographic transition to a super-aged society and reimbursed transcatheter therapiesThe primary catalyst driving South Korea’s cardiovascular devices market is the nation's rapid demographic shift into a super-aged society where over 20% of the population is aged 65 or older coupled with proactive National Health Insurance (NHI) reimbursement policy expansions. Advanced age brings a high clinical incidence of degenerative valvular heart diseases (such as severe aortic stenosis and mitral regurgitation) alongside complex, multi-vessel coronary artery disease.Challenge: Rigid MFDS approval mandates, HIRA pricing pressures, and regional workforce gapsA major structural hurdle for medical device suppliers operating in South Korea is navigating stringent pre-market approval pathways enforced by the Ministry of Food and Drug Safety (MFDS) alongside ongoing reimbursement price-containment measures by HIRA. High-risk Class III and Class IV cardiovascular implants such as structural heart valves, cardiac pacemakers, and drug-eluting stents face extensive regulatory evaluation timelines (often averaging 18 to 22 months) due to mandatory, exhaustive durability bench-testing, thrombogenicity profiling, and localized clinical evidence requirements.Trend: Adoption of SaMD platforms, smart telemetry, and AI-driven remote careA dominant structural trend transforming cardiovascular care across South Korea is the rapid deployment of Software as a Medical Device (SaMD), AI-enabled rhythm analytics, and remote cardiac monitoring. Accelerated by federal Smart Hospital grants and updated regulatory pathways for digital health technologies, South Korean cardiologists are embedding cloud-connected continuous cardiac telemetry into chronic care workflows.Segment AnalysisSouth Korea Cardiovascular Devices By Device Type• South Korea’s therapeutic and surgical cardiovascular-device segment is characterized by advanced implantable technologies, sophisticated electrophysiology, minimally invasive intervention, and an increasingly structured regulatory pathway for digital and high-technology devices. The product landscape includes coronary stents, pacemakers, implantable cardioverter-defibrillators, cardiac-resynchronization systems, ablation technologies, prosthetic and transcatheter valves, vascular implants, and mechanical circulatory-support systems. The Ministry of Food and Drug Safety (MFDS) operates a risk-based medical-device classification and approval framework, while recent regulatory developments have created more formal pathways for digital medical products and AI-enabled technologies.• South Korea’s diagnostic and monitoring segment is increasingly distinguished by AI-assisted interpretation, connected diagnostics, wearable sensing, and remote cardiac-device surveillance.

In addition to ECG, Holter monitoring, cardiac imaging, telemetry, and physiological monitoring, the regulatory environment explicitly accommodates AI-based medical devices used to diagnose, manage, or predict disease, including clinical decision-support and computer-aided diagnostic software. South Korea has also established a dedicated framework for digital medical products incorporating AI, ICT, robotics, and other advanced technologies. These developments create a cardiovascular monitoring environment where software can become an active part of diagnosis and clinical decision-making rather than merely an accessory to conventional monitoring equipment. South Korea Cardiovascular Devices By Application• South Korea’s CAD device segment is characterized by highly specialized catheter-based intervention supported by advanced coronary imaging and increasingly sophisticated procedural technologies. The ecosystem includes angiography, guidewires, balloons, drug-eluting stents, intravascular imaging, atherectomy, and other catheter-laboratory systems. A distinctive feature is the close relationship between device development and sophisticated tertiary-care cardiology, where complex coronary intervention can be integrated with advanced imaging and multidisciplinary decision-making. The broader MFDS framework also places increasing emphasis on clinical evidence and technology-specific evaluation, creating a pathway in which innovative coronary devices can incorporate digital functions alongside conventional mechanical components.• South Korea’s heart-failure device segment is increasingly focused on continuous disease management through implantable therapy, physiological monitoring, and digitally connected follow-up.

Relevant technologies include cardiac-resynchronization systems, ICDs, pacemakers, ventricular-assistance devices, and emerging sensor-based monitoring platforms. A particularly distinctive aspect is the development of remote monitoring for cardiac implantable electronic devices. Korean clinical research has examined remote monitoring of pacemakers, ICDs, and CRT devices and its integration into routine follow-up, illustrating how implanted cardiovascular technologies can become ongoing sources of clinical information rather than devices used only during periodic hospital visits.• South Korea’s cardiac-arrhythmia segment combines electrophysiological mapping, catheter ablation, implanted rhythm-management devices, and remote device surveillance. Pacemakers, ICDs, CRT systems, implantable cardiac monitors, mapping platforms, and ablation catheters address different stages of rhythm diagnosis and treatment. Remote monitoring has become a particularly relevant technology area: Korean clinical studies have examined home monitoring of implanted pacemakers, ICDs, and CRT devices, with device-generated alerts reviewed by clinical teams. This creates a distinctive market environment in which device programming, connectivity, alert management, and long-term specialist follow-up are increasingly interconnected.• South Korea’s structural-heart segment is characterized by transcatheter intervention, sophisticated cardiac imaging, and integration of procedural technologies with specialized cardiovascular centers.

The device landscape includes surgical and transcatheter heart valves, valve-repair systems, delivery catheters, occlusion devices, and imaging technologies used for anatomical assessment and procedural guidance. The broader MFDS regulatory environment supports dedicated review of innovative medical technologies, while the increasing incorporation of digital and AI capabilities into medical devices creates opportunities for imaging systems and procedure-support technologies to become more automated and clinically integrated.• Other cardiovascular applications encompass vascular intervention, emergency cardiac care, mechanical circulatory support, congenital-heart procedures, intensive-care monitoring, cardiovascular rehabilitation, and digital cardiovascular technologies. South Korea’s expanding definition and regulatory infrastructure for digital medical products is particularly relevant to this broad category because digital devices can incorporate AI, independent software, robotics, ICT, digital-twin technologies, and other advanced technologies for diagnosis, monitoring, treatment, prediction, and rehabilitation. This means the cardiovascular-device ecosystem increasingly extends beyond conventional implants and surgical instruments into software-driven and connected healthcare solutions. South Korea Cardiovascular Devices By End-User• Hospitals and cardiac centers are the principal environment for complex cardiovascular intervention, electrophysiology, cardiac surgery, structural-heart procedures, implantation, and advanced diagnostic imaging. These institutions provide catheterization laboratories, operating rooms, electrophysiology suites, intensive-care infrastructure, and specialist teams needed for high-complexity cardiovascular procedures. They are also important environments for adopting emerging technologies because clinical evidence, specialist training, procedural expertise, and device follow-up can be concentrated within tertiary-care institutions.

The development of remote cardiac-device monitoring in Korean hospitals further demonstrates how institutional cardiology services are extending beyond conventional in-person follow-up.• South Korea does not directly mirror the U.S. ASC model; outpatient and shorter-stay cardiovascular procedures are more closely integrated into hospital-based outpatient services and specialized healthcare facilities. The growth of minimally invasive cardiovascular intervention can support shorter procedural pathways for appropriately selected patients, particularly where advanced imaging, catheter-based systems, and streamlined recovery protocols are available. Devices that reduce procedural complexity, minimize surgical trauma, and facilitate predictable post-procedure observation are therefore relevant to this setting, while highly complex cardiovascular procedures continue to require the infrastructure and emergency capabilities of specialized hospitals.• Specialty clinics are increasingly relevant to cardiac diagnostics, arrhythmia management, electrophysiology follow-up, chronic heart-failure care, rehabilitation, and implanted-device surveillance. Portable ECG systems, Holter monitors, wearable sensors, and software-enabled diagnostic platforms can extend specialist cardiovascular assessment beyond tertiary hospitals. South Korea’s regulatory framework for AI-based and digital medical devices supports this transition by formally recognizing software used for diagnosis, disease management, prediction, and clinical decision support.• South Korea’s home-care cardiovascular-device segment is developing around remote monitoring, wearable technologies, connected implantable devices, and digitally supported chronic cardiovascular management.

Remote monitoring of cardiac implantable electronic devices has already been investigated in South Korean clinical settings, providing a foundation for follow-up models in which pacemakers, ICDs, and CRT systems transmit information to healthcare professionals without requiring every assessment to occur in person. The emergence of a broader national framework for digital medical products further supports connected home-based technologies, while making cybersecurity, patient usability, data interpretation, and clinical alert management important considerations for home-care cardiovascular devices.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Cardiovascular Devices Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Device Type• Therapeutic and Surgical Devices• Diagnostic and Monitoring DevicesBy Application• Coronary Artery Disease (CAD) • Heart Failure • Cardiac Arrhythmia • Structural Heart Disease • Other ApplicationsBy End User• Hospitals & Cardiac Centers • Ambulatory Surgical Centers (ASCs) • Specialty Clinics • Home-Care Settings.